Gene test may help men with prostate cancer skip treatment safely

NCT ID NCT04396808

Ongoing Disease control Sponsor: University of Michigan Rogel Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a special gene test can help men with low-risk prostate cancer decide to monitor their cancer instead of treating it right away. About 805 men with early-stage prostate cancer will be randomly assigned to have the gene test or not. The goal is to see if the test helps more men safely choose active surveillance (watchful waiting) without their cancer getting worse.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Henry Ford Health System

Detroit, Michigan, 48202, United States
Montefiore Medical Center

The Bronx, New York, 10461, United States
Sherwood Medical Center

Detroit, Michigan, 48221, United States
Spectrum Health Medical Group

Grand Rapids, Michigan, 49503, United States
University of Michigan Rogel Cancer Center

Ann Arbor, Michigan, 48109, United States
University of North Carolina

Chapel Hill, North Carolina, 27599, United States
University of Pennsylvania Perelman School of Medicine

Philadelphia, Pennsylvania, 19104, United States
Western Michigan Urological Associates

Holland, Michigan, 49423, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.